JPRN-UMIN000001615已完成2 期
The efficacy and safety of gemcitabine / cisplatin combination therapy in patients with advanced refractory biliary tract cancer - Gemcitabine / cisplatin combination therapy for advanced refractory biliary tract cancer
Faculty of Medicine, University of Tokyo0 个研究点目标入组 20 人开始时间: 2009年1月3日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with an active concomitant infection 2) Patients with digestive ulcer or gastrointestinal bleeding 3) Patients with severe cardiovascular or renal disease 4) Patients with an active pulmonary fibrosis or interstitial pneumonia 5) Patients with uncontrollable massive pleural effusion or massive ascites 6) Patients with an active concomitant malignancy 7) Pregnant, lactating female and patients of reproductive potential who did not use effective contraception 8) Patients with a previous history of a severe drug hypersensitivity 9) Patients receiving anti-cancer drugs 10) Inappropriate patients for entry on this study in the judgement of the investigator
研究者
相似试验
已完成
2 期
The efficacy and the safety of gemcitabine / S-1 combination therapy in patients with advanced non-resectable or post-operative recurrent biliary tract cancer -multicenter phase II studyon-resectable or post-operative recurrent biliary tract cancerJPRN-UMIN000000590Faculty of Medicine, University of Tokyo35
进行中（未招募）
不适用
A randomized phase II study of gemcitabine/cisplatin with or without Cetuximab to evaluate the efficacy in patients with locally advanced or metastatic EGFR-positive pancreatic cancer. SpaCe TRIAL.ocally advanced or metastatic EGFR-positive pancreatic cancer.MedDRA version: 6.1Level: HLGTClassification code 10015674EUCTR2004-004309-69-ITGISCAD120
进行中（未招募）
不适用
A randomized phase II study of gemcitabine/cisplatin with or without sorafenib to evaluate the efficacy and safety in patients with locally advanced or metastatic pancreatic cancer. MAPS trial - Metastatic Advanced Pancreas SorafenibSubjects enrolled in this study must have histologically confirmed locally advanced or metastatic pancreatic adenocarcinoma. They must not have been received a first-line chemotherapy. Presence of at least one target lesion measurable by CT scan or MRI in not an irradiated area (and conform with the RECIST criteriaMedDRA version: 6.1Level: PTClassification code 10033609EUCTR2007-001781-32-ITGISCAD
招募中
不适用
Efficacy of neoadjuvant Gemcitabin-Cisplatin chemotherapy for upper urinary tract carcinoma - Randomized comtrolled traialper urinary tract carcinoma wituout distant metastasisJPRN-UMIN000010785osaka medical college department of urology100
招募中
1 期
Safety and Efficacy for Gemcitabine plus nab-paclitaxel with MK615 combination therapy in unresected/recurrent metastatic pancreatic cancer.: Phase I/II study (PC(UR-M) GEM/nab-PTX + MK615)pancreatic cancerJPRN-jRCTs061180074FUKUBA Nobuhiko35